MedPath

Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis

Phase 4
Completed
Conditions
Osteoarthritis
Pain
Interventions
Registration Number
NCT00927004
Lead Sponsor
Curtin University
Brief Summary

This study aims to better understand the way in which painful osteoarthritis affects different people and whether an anti-inflammatory medication such as Arcoxia (etoricoxib) can help to modify this pain. The study will use questionnaires and tests of pain sensitivity to identify arthritis sufferers with more widespread, nerve-type pain and then to investigate whether a daily dose of Arcoxia is more effective than a placebo pill in reducing these symptoms and improving functional movements. The study will also be comparing the same test results of a small group of subjects without knee pain.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • unilateral diagnosis of Knee OA > 6 months
  • knee pain > 4/10 on WOMAC pain subscale
  • if pain in contralateral knee, no greater than "mild"
  • no other significant joint involvement
  • ARA functional Class I, II or III
  • no arthroscopy or injections into index knee in last 6 months
Exclusion Criteria
  • history of systemic inflammatory or chronic pain disorders (especially fibromyalgia)

  • neurological deficit

  • recent (< 6 months) lower limb surgery

  • allergic reaction to NSAIDs or aspirin

  • skin allergies, dermatitis

  • contraindications to Cox-2 inhibitors:

    • congestive heart failure (NYHA II-IV)
    • unstable hypertension
    • ischaemic heart disease
    • peripheral artery disease
    • cerebrovascular disease including CABG or angioplasty within 1 year
  • severe hepatic dysfunction

  • active GI bleeding or peptic ulceration

  • reduced creatinine clearance < 30 mL/min

  • current use of high dose (> 325 mg daily) aspirin

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sugar pillSugar pill-
Etoricoxib 60 mgEtoricoxib (Arcoxia)-
Primary Outcome Measures
NameTimeMethod
Pressure Pain Threshold15 days, 3 days
Western Ontario and McMaster University Osteoarthritis Index (knee) - pain subscale15 days, 3 days
Secondary Outcome Measures
NameTimeMethod
Cold Pain Threshold15 days, 3 days
Topical Cold Response15 days, 3 days
Functional Measure (aggregated locomotor score, sit-to-stand time)15 days, 3 days
WOMAC (knee) total15 days, 3 days
SF-36v215 days, 3 days
Pain Quality Assessment Scale15 days, 3 days
PainDETECT questionnaire15 days, 3 days

Trial Locations

Locations (1)

Royal Perth Hospital

🇦🇺

Perth, Western Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath